Add BrightSurf on Google Email

Beyond


Finerenone slows kidney function decline and reduces cardiovascular-kidney risk in non-diabetic chronic kidney disease, major trial shows

The Phase III FIND-CKD trial found that finerenone significantly slowed kidney function decline and reduced the risk of cardiovascular-kidney outcomes in adults with non-diabetic chronic kidney disease. Finerenone also demonstrated a consistent effect across prespecified subgroups, supporting its broad applicability in these patients.

SourceBeyond·JournalNew England Journal of Medicine·DateJun 4, 2026

Influenza frequently missed in winter deaths, new study finds

A new study found that influenza was detected in 11% of winter deaths, but only 17% had a confirmed diagnosis before death. The study highlights the gap between detection and official mortality records, suggesting influenza may play a larger role in winter mortality than routine surveillance captures.

SourceBeyond·JournalClinical Microbiology and Infection·DateApr 9, 2026

Combination finerenone and empagliflozin shows superior efficacy in reducing albuminuria in chronic kidney disease and type 2 diabetes patients

The CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to significantly greater reductions in albuminuria than either agent alone. The study shows a 52% median reduction in urinary albumin-to-creatinine ratio, achieving the ADA-recommended target for 70% of patients.

SourceBeyond·JournalNew England Journal of Medicine·DateJun 5, 2025